Stock 603567 HEILONGJIANG ZBD PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Heilongjiang ZBD Pharmaceutical Co., Ltd.

Equities

603567

CNE100002219

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 28/06/2024 am IST 		5-day change 1st Jan Change
10.53 CNY -0.38% Intraday chart for Heilongjiang ZBD Pharmaceutical Co., Ltd. -7.14% -13.40%
27/05 ZBD Pharma Gets China Approval for Gastric Acid Inhibiting Tablets MT
07/05 China Grants Drug Registration Approval for ZBD Pharma's Anti-Epilepsy Injectable MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 10,173 10,818 9,477 14,412 11,988 11,423
Enterprise Value (EV) 1 10,068 10,963 11,146 15,792 13,853 13,105
P/E ratio 22 x 26.5 x 21.7 x 39.8 x 64.8 x 24.2 x
Yield 1.37% 1.7% - 0.69% 0.22% 1.64%
Capitalization / Revenue 3.66 x 3.29 x 2.78 x 3.49 x 2.84 x 3.64 x
EV / Revenue 3.62 x 3.33 x 3.27 x 3.83 x 3.29 x 4.18 x
EV / EBITDA 16.2 x 15.6 x 15.1 x 39.3 x -212 x 36.6 x
EV / FCF -268 x -411 x -8.33 x -17.9 x -34.2 x -17.5 x
FCF Yield -0.37% -0.24% -12% -5.58% -2.92% -5.7%
Price to Book 2.05 x 2.06 x 1.72 x 2.05 x 1.69 x 1.51 x
Nbr of stocks (in thousands) 8,49,160 8,49,160 8,49,160 9,41,964 9,40,247 9,39,403
Reference price 2 11.98 12.74 11.16 15.30 12.75 12.16
Announcement Date 25/04/19 29/04/20 29/04/21 29/04/22 28/04/23 29/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 2,781 3,292 3,404 4,127 4,214 3,138
EBITDA 1 623.1 701.2 737.2 401.7 -65.44 358.2
EBIT 1 503.5 566.4 585.3 270.5 -216.7 185.5
Operating Margin 18.1% 17.21% 17.2% 6.55% -5.14% 5.91%
Earnings before Tax (EBT) 1 550.5 537.3 537.3 454.7 298.5 478.3
Net income 1 462.4 408.6 436.3 332.1 185.4 472.7
Net margin 16.63% 12.41% 12.82% 8.05% 4.4% 15.06%
EPS 2 0.5446 0.4800 0.5138 0.3841 0.1969 0.5029
Free Cash Flow 1 -37.63 -26.69 -1,337 -881.6 -404.7 -746.7
FCF margin -1.35% -0.81% -39.29% -21.36% -9.6% -23.8%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 0.1640 0.2170 - 0.1060 0.0280 0.2000
Announcement Date 25/04/19 29/04/20 29/04/21 29/04/22 28/04/23 29/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 145 1,669 1,380 1,865 1,682
Net Cash position 1 105 - - - - -
Leverage (Debt/EBITDA) - 0.2066 x 2.264 x 3.436 x -28.5 x 4.694 x
Free Cash Flow 1 -37.6 -26.7 -1,337 -882 -405 -747
ROE (net income / shareholders' equity) 9.59% 7.93% 8.14% 5.3% 2.7% 6.17%
ROA (Net income/ Total Assets) 4.18% 4.12% 3.8% 1.56% -1.17% 0.96%
Assets 1 11,072 9,928 11,480 21,356 -15,866 49,218
Book Value Per Share 2 5.860 6.170 6.470 7.480 7.560 8.040
Cash Flow per Share 2 2.660 3.010 1.810 1.650 1.070 1.550
Capex 1 420 179 869 449 404 95.1
Capex / Sales 15.09% 5.43% 25.52% 10.87% 9.59% 3.03%
Announcement Date 25/04/19 29/04/20 29/04/21 29/04/22 28/04/23 29/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
HEILONGJIANG ZBD PHARMACEUTICAL CO., LTD. Stock Heilongjiang ZBD Pharmaceutical Co., Ltd.
-13.40% 1.36B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 815B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 314B
ABBVIE INC. Stock AbbVie Inc.
+10.68% 303B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 242B
ROCHE HOLDING AG Stock Roche Holding AG
+2.04% 224B
NOVARTIS AG Stock Novartis AG
+13.31% 218B
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
PFIZER, INC. Stock Pfizer, Inc.
-2.81% 159B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 603567 Stock
  4. Financials Heilongjiang ZBD Pharmaceutical Co., Ltd.